Efficacy of Combined Encorafenib and Binimetinib Treatment for Erdheim–Chester Disease Harboring Concurrent BRAFV600E and KRASG12R Mutations: A Case Report

Efficacy of Combined Encorafenib and Binimetinib Treatment for Erdheim–Chester Disease Harboring Concurrent BRAFV600E and KRASG12R Mutations: A Case Report

ABSTRACT Background Erdheim–Chester disease (ECD) is a rare form of non‐Langerhans cell histiocytosis with diverse clinical manifestations, often associated with mutations in the mitogen‐activated protein kinase/extracellular signal‐regulated kinase (MAPK/ERK) pathway. BRAF and KRAS mutations, which...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuto Hibino, Rika Sakai, Hiroyuki Takahashi, Takaaki Takeda, Natsuki Hirose, Mayumi Tokunaga, Kota Washimi, Tomoyuki Yokose, Rika Kasajima, Yukihiko Hiroshima, Yohei Miyagi, Hideaki Nakajima
Format: Article
Language:English
Published: Wiley 2024-12-01
Series:Cancer Reports
Subjects:
BRAF inhibitor
Erdheim–Chester disease
genomic profiling
histiocytosis
MEK inhibitor
molecular‐targeted therapy
Online Access:https://doi.org/10.1002/cnr2.70093
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cnr2.70093

Similar Items